StreetInsider.com News Articles

Form 8-K Arcadia Biosciences, For: Jun 11

Mon, 15 Jun 2026 11:32:00 -0400

si-local-file:///var/storage/secattach/20260615/26645970.html

Form 8-K Arcadia Biosciences, For: Jun 11

Mon, 15 Jun 2026 11:32:00 -0400

si-local-file:///var/storage/secattach/20260615/26645970.html

Arcadia Biosciences closes $4 million private placement

Fri, 12 Jun 2026 22:00:09 -0400

Arcadia Biosciences Inc. (NASDAQ: RKDA) announced the completion of a $4 million private placement involving the sale of 3,883,496 shares of common stock and associated investment options.

The Dallas-based wellness products company sold shares at $1.03 per share, with H.C. Wainwright & Co. serving as the exclusive placement agent. The offering included Series A-1 and Series A-2 preferred investment options, each allowing the purchase of up to 3,883,496 additional shares at an exercise price of $0.91 per share.

The Series A-1 options become exercisable after stockholder approval and expire five years from that approval date. The Series A-2 options are immediately exercisable

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Fri, 12 Jun 2026 22:00:00 -0400

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Fri, 12 Jun 2026 22:00:00 -0400

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Fri, 12 Jun 2026 22:00:00 -0400

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Fri, 12 Jun 2026 22:00:00 -0400

Arcadia Biosciences raises $4 million in private placement

Thu, 11 Jun 2026 20:00:09 -0400

Arcadia Biosciences Inc. (NASDAQ: RKDA) announced it entered into securities purchase agreements for a $4 million private placement priced at-the-market under Nasdaq rules.

The company will sell 3,883,496 shares of common stock or pre-funded warrants at $1.03 per share. The offering includes Series A-1 and Series A-2 preferred investment options to purchase up to 3,883,496 shares each of common stock.

The Series A-1 options carry an exercise price of $0.91 per share and will be exercisable after stockholder approval, expiring five years from the approval date. The Series A-2 options have the same exercise price and are exercisable immediately upon issuance, expiring

Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Thu, 11 Jun 2026 20:00:00 -0400

DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today that it has entered into securities purchase agreements for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock

Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Thu, 11 Jun 2026 20:00:00 -0400

Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Thu, 11 Jun 2026 20:00:00 -0400

Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Thu, 11 Jun 2026 20:00:00 -0400

Form SCHEDULE 13G Arcadia Biosciences, Filed by: ARMISTICE CAPITAL, LLC

Fri, 15 May 2026 11:29:00 -0400

si-local-file:///var/storage/secattach/20260515/26502205.html

Form SCHEDULE 13G Arcadia Biosciences, Filed by: ARMISTICE CAPITAL, LLC

Fri, 15 May 2026 11:29:00 -0400

si-local-file:///var/storage/secattach/20260515/26502205.html

Form 10-Q Arcadia Biosciences, For: Mar 31

Thu, 14 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260514/26494810.html

Form 10-Q Arcadia Biosciences, For: Mar 31

Thu, 14 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260514/26494810.html

Form 8-K Arcadia Biosciences, For: May 14

Thu, 14 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260514/26494723.html

Form 8-K Arcadia Biosciences, For: May 14

Thu, 14 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260514/26494723.html

Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights

Thu, 14 May 2026 16:05:00 -0400

-- Zola^® volumes increase 18% year-over-year --

-- SG&A at lowest level in Arcadia’s history --

DALLAS, May 14, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the first quarter of 2026.

“We are very pleased with our performance during the first quarter of 2026,” said T.J. Schaefer, CEO of Arcadia. “We were able to bring in gross proceeds of approximately $2.1 million from the exercise of previously outstanding preferred investment options, Zola^®

Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights

Thu, 14 May 2026 16:05:00 -0400

-- Zola^® volumes increase 18% year-over-year --

-- SG&A at lowest level in Arcadia’s history --

Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights

Thu, 14 May 2026 16:05:00 -0400

-- Zola^® volumes increase 18% year-over-year --

-- SG&A at lowest level in Arcadia’s history --

Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights

Thu, 14 May 2026 16:05:00 -0400

-- Zola^® volumes increase 18% year-over-year --

-- SG&A at lowest level in Arcadia’s history --

Form 10-K/A Arcadia Biosciences, For: Dec 31

Thu, 30 Apr 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260430/26408278.html

Form 10-K/A Arcadia Biosciences, For: Dec 31

Thu, 30 Apr 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260430/26408278.html

Form 8-K Arcadia Biosciences, For: Mar 30

Fri, 03 Apr 2026 15:31:00 -0400

si-local-file:///var/storage/secattach/20260403/26271525.html